Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Wright Reports
$75.00
Provider: Thomson Reuters Stock Report
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

HANS BIOMED CORP receives approval from FDA


Wednesday, 15 Jan 2014 08:28pm EST 

HANS BIOMED CORP:Says received an approval from Food and Drug Administration (FDA), the United States, for SurFuse Gel/Putty, ExFuse Gel/Putty, which is a dental demineralized bone matrix (DBM) product for bone graft.Says 510(K) number of K130235. 

Company Quote

22350.0
-200.0 -0.89%
27 Mar 2015